Skip to main content
    O

    Oramed Pharmaceuticals Inc (ORMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.90
    +0.19 (+5.12%)

    Market Cap: $161.33M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Oramed Pharmaceuticals Inc (ORMP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Oramed Pharmaceuticals reported revenue of $2.00M for the fiscal year ended Dec 31, 2025. That year, net income was $64.05M with a net margin of 3202.5%, operating cash flow was -$9.14M and free cash flow was -$11.08M. The quarter ended Sep 30, 2026 had net income of $18.41M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $641.00K, a compound annual rate of 13.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.00MN/A0.7%-754.4%3202.5%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$1.34M-50.4%100.0%-1176.8%412.3%
    Dec 2022$2.70M0.0%100.0%-1502.0%-1397.1%
    Dec 2021$2.70M-0.3%100.0%-896.2%-822.7%
    Dec 2020$2.71M+0.3%100.0%-433.8%-424.8%
    Dec 2019$2.70M+10.4%96.7%-541.3%-531.1%
    Dec 2018$2.45M-0.3%96.5%-552.3%-519.7%
    Dec 2017$2.46M+283.2%92.4%-438.6%-426.7%
    Dec 2016$641.00KN/A23.6%-1561.6%-1710.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 62.0% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.00M$0$1.34M$2.70M$2.70M$2.71M$2.70M$2.45M$2.46M$641.00K
    Cost of revenue$1.99M$193.00KN/AN/AN/A$90.00K$90.00K$86.00K$187.00K$490.00K
    Gross profit$13.00K-$193.00K$1.34M$2.70M$2.70M$2.71M$2.61M$2.36M$2.27M$151.00K
    Research and development$6.38M$6.32M$8.97M$27.64M$20.99M$10.23M$13.52M$11.98M$10.28M$7.71M
    Operating income-$15.09M-$12.78M-$15.77M-$40.60M-$24.22M-$11.76M-$14.63M-$13.53M-$10.77M-$10.01M
    Net income$64.05M-$19.06M$5.53M-$37.76M-$22.24M-$11.51M-$14.36M-$12.73M-$10.48M-$10.96M
    EBITDA$75.44MN/A$7.32M-$40.54M-$24.15M-$11.75M-$14.17M-$13.49M-$10.76M-$9.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    RevenueN/A$0$0$0$0$0$2.00M$0$0$0$0$0
    Gross profitN/A$0-$30.00K-$30.00K-$31.00K-$30.00K$13.00K-$31.00K-$52.00K-$54.00K-$56.00K-$53.00K
    Operating income-$4.10M-$2.77M-$3.66M-$5.67M-$2.43M-$2.49M-$4.50M-$3.60M-$3.09M-$3.13M-$2.96M-$3.88M
    Net income$18.41M$78.16M$38.31M$10.01M$48.40M$13.29M-$7.64M-$10.19M-$19.62M$9.21M$1.54M$13.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $285.00K by $45.66M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$230.86M$155.28M$220.55M$161.64M$128.00M$44.63M$34.66M$47.40M$38.71M$42.83M
    Current assets$133.27M$143.22M$162.58M$157.11M$95.34M$40.51M$33.32M$31.04M$20.30M$31.23M
    Cash and equivalents$45.95M$54.42M$9.05M$40.46M$77.25M$19.30M$3.33M$5.00M$3.97M$3.91M
    Total liabilities$31.12M$9.93M$57.66M$10.49M$11.48M$11.75M$15.27M$16.29M$19.47M$16.64M
    Short-term debt$285.00K$216.00K$51.28M$247.00K$130.00K$44.00KN/AN/AN/AN/A
    Shareholder equity$199.74M$146.26M$163.82M$151.81M$115.77M$32.88M$19.39M$31.11M$19.24M$26.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$400.92M$369.64M$268.85M$230.86M$220.49M$161.68M$147.54M$155.28M$165.08M$184.22M$203.65M$220.55M
    Total liabilities$61.83M$52.17M$30.57M$31.12M$18.16M$8.10M$7.64M$9.93M$9.56M$8.07M$37.93M$57.66M
    Cash and equivalents$28.93M$15.24M$13.20M$45.95M$52.18M$15.80M$74.52M$54.42M$42.10M$84.75M$18.58M$9.05M
    Shareholder equity$339.09M$317.47M$238.28M$199.74M$203.28M$154.53M$140.81M$146.26M$156.44M$177.06M$166.64M$163.82M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.14M-$8.41M-$10.29M-$28.70M-$21.18M-$12.44M-$12.94M-$14.66M-$5.83M$4.66M
    Capital expenditures$1.93M$18.00K$254.00K$496.00K$375.00K$82.00K$15.00K$5.00K$7.00K$9.00K
    Free cash flow-$11.08M-$8.43M-$10.55M-$29.20M-$21.56M-$12.52M-$12.95M-$14.66M-$5.84M$4.65M
    Dividends paid$10.87MN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$5.44M$105.82M-$73.04M$30.21M-$22.26M$4.63M$11.26M-$7.00M$4.30M-$16.01M
    Financing cash flow-$4.74M-$52.04M$51.98M$11.56M$101.39M$23.79MN/A$22.65M$1.59M$12.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$426.00K-$200.00K-$2.92M-$466.00K-$1.63M-$3.54M-$3.52M-$1.94M-$7.07M$2.07M-$1.48M-$1.34M
    Capital expenditures$4.00K$2.00K$5.00K$202.00K$289$4.03K$3.00K$11.02K$4.98KN/A$2.00K$2.00K
    Free cash flow$422.00K-$202.00K-$2.92M-$668.00K-$1.63M-$3.54M-$3.52M-$1.95M-$7.08MN/A-$1.48M-$1.34M
    Last 12 quarters

    Frequently Asked Questions About ORMP

    What is Oramed Pharmaceuticals' annual revenue?

    Oramed Pharmaceuticals reported revenue of $2.00M for the fiscal year ended Dec 31, 2025.

    Is Oramed Pharmaceuticals profitable?

    Yes. Oramed Pharmaceuticals reported net income of $64.05M for the fiscal year ended Dec 31, 2025, with a net margin of 3202.5%.

    How much free cash flow does ORMP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.14M minus capital expenditures of $1.93M produced free cash flow of -$11.08M.

    How much debt does Oramed Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $285.00K and cash and equivalents of $45.95M.

    What is ORMP's profit margin?

    For the fiscal year ended Dec 31, 2025, Oramed Pharmaceuticals reported gross margin of 0.7%, operating margin of -754.4% and net margin of 3202.5%.